The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6

Schizophrenia Research

Volumn 32, Issue 1, 1998, Pages 9-15

  Lin, A ^a,b   Kenis, G ^c,d   Bignotti, S ^e   Tura, G J B ^e   De Jong, R ^c   Bosmans, E ^d   Pioli, R ^e   Altamura, C ^e,f   Scharpe S ^b   Maes, M ^a,e,g  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Department of Anesthesiology AZ ^*  (Belgium)

^d Eurogenetics   (Belgium)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g VANDERBILT UNIVERSITY   (United States)

Author keywords

CC16; Cytokines; Inflammation; Interleukin 6; Neuroleptics; Treatment resistant schizophrenia

Indexed keywords

CYTOKINE; INTERLEUKIN 6; NEUROLEPTIC AGENT;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL ARTICLE; DRUG EFFECT; FAMILY HISTORY; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032557948     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00034-6     Document Type: Article

References (34)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC.
2. Benigni F., Fantuzzi G., Sacco S., Sironi M., Pozzi P., Dinarello C.A., Sipe J.D., Poli V., Cappelletti M. Six different cytokines that share GP 130 as receptor subunit. Blood. 87:1996;1851-1854.
3. Bernard A., Roels H., Lauwerys R., Gielens C., Soumillion A., Van Damme J., De Ley M. Human urinary protein 1: evidence for identity with the Clara cell protein and occurrence in respiratory tract and urogenital secretions. Clin. Chim. Acta. 207:1992;239-249.
4. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Med. Inflamm. 2:1993;3-21.
5. DeLisi L.E., Crow T.J. Is schizophrenia a viral or immunological disorder? Psychiatr. Clin. N. Am. 9:1986;115-132.
6. Dierynck I., Bernard A., Roels H., De Ley M. Potent inhibition of both human interleukin-γ production and biologic activity by the Clara cell protein CC16. Am. J. Respir. Cell. Mol. Biol. 12:1995;205-210.
7. Gearing D.P., Comeau M.R., Friend D.J., Gimple S.D., Thut C.J., Mcgourty J., Brasher K.K., King J.A., Gills S., Mosley B., Ziegler S.F., Cosman D. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 255:1992;1434-1437.
8. Howell, D.C., 1982. Statistical Methods for Psychology. Duxbury Press, Boston, MA, pp. 378-399.
9. Ip N.Y., Nye S.H., Boulton T.G., Davis S., Taga T., Li Y., Birren S.J., Yasukawa K., Kishimoto T., Anderson D.J., Stahl N., Yancopoulos G.D. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 69:1992;1121-1132.
10. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
11. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
12. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19:1993;355-370.
13. Maes M., Scharpe S., Meltzer H.Y., Bosmans E., Suy E., Calabrese J., Cosyns P. Relationships between interleukin-6 activity, acute phase proteins and HPA-axis function in severe depression. Psychiatry Res. 49:1993;11-27.
14. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
15. Maes M., Stevens S., Scharpe S., Bosmans E., De Meyer F., D'Hondt P., Peeters D., Thompson P., Cosyns P., De Clerck L. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia. 50:1994;821-829.
16. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatry Res. 29:1995;141-152.
17. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:1996;39-50.
18. Maes M., Bosmans E., Kenis G., DeJong R., Smith R., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:1997;221-225.
19. Maes M., Delanghe J., Ranjan R., Meltzer H.Y., Desnyder R., Cooreman W., Scharpe S. The acute phase protein response in schizophrenia, mania and major depression: effects of psychotropic drugs. Psychiatry Res. 66:1997;1-11.
20. Maes, M., Song, C., Lin, A., DeJong, R., Van Gastel, A., Kenis, G., Bosmans, E., De Meester, I., Benoy, I., Neels, H., Demedts, P., Janca, A., Scharpé, S., Smith, R.S. (in press) The effects of psychological stress on humans: increased production of proinflammatory cytokines and a Th-1-like response in stress-induced anxiety. Cytokine.
21. Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for IL-6Rα-induced AIDS-KS cell growth. Int. Immunol. 8:1996;595-602.
22. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
23. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:1996;403-409.
24. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., Paul S.M. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch. Gen. Psychiatry. 46:1989;291-292.
25. Rhoades H.M., Overall J.E. The semistructured BPRS interview and rating guide. Psychopharmacol. Bull. 10:1988;101-104.
26. Saito T., Taga T., Miki D., Futatsugi K., Yawata H., Kishimoto T., Yasukawa K. Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated function. J. Immunol. Meth. 163:1993;217-223.
27. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuga M., Suzuki E., Kinoshita N., Yagi G. Serum interleukin-6 in schizophrenic patients. Life Sci. 49:1991;661-664.
28. Singh G., Katyal S.L. An immunological study of the secretory products of rat Clara cells. J. Histochem. Cytochem. 32:1984;49-54.
29. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;75-83.
30. Smith R., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypoth. 45:1995;135-141.
31. Smith R.S. Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? Med. Hypoth. 34:1991;225-229.
32. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypoth. 39:1992;248-257.
33. Yamasaki K., Taga Y., Hirata Y., Yawata H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor. Science. 241:1988;825-828.
34. Yin T., Yaga T., Tsang M.L.-S., Yasukawa K., Kishimoto T., Yang Y.-C. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J. Immunol. 151:1993;2555-2561.